Inhalation Sciences signs IRS contract worth 1.39 million SEK with new US respiratory pharma client Kumar Jeetendra | September 16, 2022 The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB’s leading in vitro lung simulation tool DissolvIt®. DissolvIt® has been increasingly recognized in the inhalation industry as a leading …
